This approach could be useful for the treatment of a multitude of brain disorders that result from the overexpression of epigenetic regulators (such as BRWD1 in Down syndrome), or when there is a global imbalance of histone PTMs due to LoF mutations. This evidence concerns the gene BRWD1 and Down syndrome.